Korean Pharma ‘Desperate’ For Improved Pricing System
This article was originally published in PharmAsia News
In their efforts to catch up with Hanmi Pharmaceutical, which has clinched a series of record licensing out deals this year, other pharma companies in South Korea are looking for government support to create a more industry-friendly drug pricing environment. During a recent meeting with the new health minister, industry associations urged the government to improve the system to better reward R&D investments.
Register for our free email digests: